Blair, Gordon W <br/><br/>
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination.  [electronic resource] 

 -  International journal of stroke : official journal of the International Stroke Society  07 2018 
 - 530-538 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1747-4949 
<br/><br/><label>Standard No.: </label>10.1177/1747493017731947  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Cerebral Small Vessel Diseases--complications<br/>Cilostazol--therapeutic use<br/>Cognition Disorders--etiology<br/>Dementia--etiology<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Isosorbide Dinitrate--analogs & derivatives<br/>Magnetic Resonance Imaging<br/>Male<br/>Neuropsychological Tests<br/>Severity of Illness Index<br/>Treatment Outcome<br/>United Kingdom<br/>Vasodilator Agents--therapeutic use